89 PART II ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Our common stock has been listed on the Nasdaq Global Market under the symbol “KOD” since October 4, 2018. Prior to this date, there was no public market for our common stock. Holders of Common Stock As of March 6, 2019, there were approximately 103 holders of record of our common stock. The approximate number of holders is based upon the actual number of holders registered in our records at such date and excludes holders in “street name” or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies. Stock Performance Graph The following graph is not “soliciting material” or deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that Section, and shall not be deemed incorporated by reference into any filing of Kodiak Sciences Inc. under the Securities Act of 1933, as amended (the “Securities Act”), whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. The following graph compares the cumulative total stockholder return on our common stock with the cumulative total return of the Nasdaq Composite Index and the Nasdaq Biotechnology Index for an investment of $100, between October 4, 2018 (the date of our initial public offering) and December 31, 2018. The stockholder returns shown in the graph below are based on historical results and are not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns. Dividend Policy We have never declared or paid any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. Securities Authorized for Issuance under Equity Compensation Plans Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K. $60 $80 $100 $120 10/4/2018 12/31/2018 COMPARISON OF CUMULATIVE TOTAL RETURN among Kodiak Sciences Inc., the Nasdaq Composite Index, and the Nasdaq Biotechnology Index Kodiak Sciences Inc. Nasdaq Composite Index Nasdaq Biotechnology Index